异基因造血干细胞移植治疗慢性粒细胞白血病的疗效

Efficacy of allogeneic hematopoietic stem cell transplantation in the treatment of patients with chronic myeloid leukemia

目的观察异基因造血干细胞移植(allo-HSCT)治疗慢性粒细胞白血病(CML)的疗效。方法回顾性分析allo-HSCT 40例CML患者的临床资料。结果 40例患者随访13-106个月,31例存活(77.5%)。移植前疾病状态和移植后是否合并巨细胞病毒感染可显著影响患者生存期;是否合并慢性移植物抗宿主病(GVHD)可影响患者生存质量。结论 allo-HSCT可使部分CML患者获得长期无病存活。慢性期移植及控制移植后的感染是提高生存的关键;预防并控制慢性GVHD可显著改善生存质量。

Objective To observe the efficacy of allogeneic hematopoietic stem cell transplantation（allo-HSCT） in the treatment of patients with chronic myeloid leukemia （CML）. Methods Data of 40 CML patients received allo-HSCT treatment were retrospectively analyzed. Results The patients were followed up for 13-106 months with a survival rate of 77.5% （31/40）. Disease phase before transplantation and CMV infection were the main factors to affect survival. The survival quality was affected by chronic graft-versus-host disease（CGVHD）. Conclusion A long-term disease-free survival can be obtained by allo-HSCT in part of the patients with CML. The key points for improving the survival are making allo-HSCT in chronic phase of CML and effectively controlling infection after transplantation. The survival quality can be improved by prevention and treatment of CGVHD.